• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by GRAIL Inc.

    8/14/24 4:49:48 PM ET
    $GRAL
    Medical Specialities
    Health Care
    Get the next $GRAL alert in real time by email
    SC 13G 1 d869907dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    GRAIL, INC.

    (Name of Issuer)

    Common Stock, $0.001 par value

    (Title of Class of Securities)

    384747 101

    (CUSIP Number)

    June 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 384747 101    SCHEDULE 13G    Page 2 of 5

     

     1   

     NAME OF REPORTING PERSON

     

     Illumina, Inc.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     4,502,126 (See Note 1)

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     4,502,126 (See Note 1)

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,502,126 (See Note 1)

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     14.5% (See Note 2)

    12  

     TYPE OF REPORTING PERSON

     

     CO

     

     

    Note 1:

    On June 24, 2024, Illumina, Inc. (“Illumina”) completed the separation of GRAIL, Inc. (the “Company”) through the distribution of approximately 85.5% of the shares of the Company’s common stock, par value $0.001 (“Common Stock”), to holders of Illumina’s common stock (the “Spin-Off”). Immediately following the Spin-Off, Illumina directly owned 4,502,126 shares, or approximately 14.5%, of the outstanding shares of Common Stock. Pursuant to a Stockholder and Registration Rights Agreement, dated as of June 21, 2024 (the “Stockholder and Registration Rights Agreement”), between Illumina and the Company, Illumina granted to the Company a proxy to vote the shares of Common Stock owned by Illumina immediately after the distribution in proportion to the votes cast by the Company’s other stockholders.

    Note 2:

    The denominator for this calculation is based on 31,049,148 shares of Common Stock outstanding as of August 11, 2024, as reported in the Company’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 13, 2024.


    CUSIP No. 384747 101    SCHEDULE 13G    Page 3 of 5

     

    Item 1.    (a)    Name of Issuer:
          GRAIL, Inc.
       (b)    Address of Issuer’s Principal Executive Offices:
          1525 O’Brien Drive, Menlo Park, CA 94025
    Item 2.    (a)    Name of Person Filing:
          Illumina, Inc.
       (b)    Address of Principal Business Office, or if none, Residence:
          5200 Illumina Way, San Diego, CA 92122
       (c)    Citizenship:
          Delaware
       (d)    Title of Class of Securities:
          Common Stock, $0.001 par value
       (e)    CUSIP Number:
          384747 101
    Item 3.    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       Not applicable.
    Item 4.    Ownership.
       (a)-(c)   
       The responses of the Reporting Person to Rows 5, 6, 7, 8, 9 and 11 in the cover page to this Section 13G are incorporated herein by reference.
       Additional Note: On June 24, 2024, Illumina completed the Spin-Off. Immediately following the Spin-Off, Illumina directly owned 4,502,126 shares, or approximately 14.5% of the outstanding shares of Common Stock. Pursuant to the Stockholder and Registration Rights Agreement, Illumina granted to the Company a proxy to vote the shares of Common Stock owned by Illumina in proportion to the votes cast by the Company’s other stockholders.


    CUSIP No. 384747 101    SCHEDULE 13G    Page 4 of 5

     

    Item 5.    Ownership of Five Percent or Less of a Class.
       Not applicable.
    Item 6.    Ownership of More than Five Percent on Behalf of Another Person.
       Not applicable.
    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       Not applicable.
    Item 8.    Identification and Classification of Members of the Group.
       Not applicable.
    Item 9.    Notice of Dissolution of Group.
       Not applicable.
    Item 10.    Certifications.
       Not applicable.


    CUSIP No. 384747 101    SCHEDULE 13G    Page 5 of 5

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: August 14, 2024

     

    ILLUMINA, INC.
    By:   /s/ ANKUR DHINGRA
      Name: Ankur Dhingra
      Title: Chief Financial Officer
    Get the next $GRAL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRAL

    DatePrice TargetRatingAnalyst
    4/21/2025$32.00Buy
    Canaccord Genuity
    11/27/2024$16.00Equal-Weight
    Morgan Stanley
    11/15/2024Peer Perform
    Wolfe Research
    10/17/2024Neutral
    Guggenheim
    More analyst ratings

    $GRAL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Ding Chun R bought $1,024,698 worth of shares (78,829 units at $13.00) and acquired $879,900 worth of shares (70,000 units at $12.57) (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      10/10/24 7:45:32 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    SEC Filings

    See more
    • GRAIL Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - GRAIL, Inc. (0001699031) (Filer)

      5/16/25 4:05:53 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • SEC Form S-8 filed by GRAIL Inc.

      S-8 - GRAIL, Inc. (0001699031) (Filer)

      5/14/25 4:21:27 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by GRAIL Inc.

      10-Q - GRAIL, Inc. (0001699031) (Filer)

      5/14/25 4:11:41 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by GRAIL Inc.

      SC 13G - GRAIL, Inc. (0001699031) (Subject)

      11/14/24 3:35:14 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by GRAIL Inc.

      SC 13G - GRAIL, Inc. (0001699031) (Subject)

      11/12/24 4:47:47 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by GRAIL Inc.

      SC 13G/A - GRAIL, Inc. (0001699031) (Subject)

      9/30/24 6:42:39 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Leadership Updates

    Live Leadership Updates

    See more
    • GRAIL Appoints Sarah Krevans to Board of Directors

      MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health, a Northern

      10/21/24 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Wheels Up Announces Gregory Summe to Join Board of Directors

      Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

      8/8/24 8:05:00 AM ET
      $AVTR
      $GRAL
      $NXPI
      $STT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care

    $GRAL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GRAIL to Present at Jefferies Global Healthcare Conference 2025

      MENLO PARK, Calif., May 21, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Jefferies Global Healthcare Conference 2025 in New York on Tuesday, June 4 at 11:40 a.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event. About GRAILGRAIL is a healthcare company whose mission is to

      5/21/25 4:05:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL Reports First Quarter 2025 Financial Results

      Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Cash Position of $677.9 Million Provides Runway Into 2028 MENLO PARK, Calif., May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025. Total revenue in the first quarter was $31.8 million, representing 19% growth year over year, and Galleri revenue was $29.1 m

      5/13/25 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL and athenahealth Team Up to Offer Healthcare Providers Streamlined Ordering of GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test

      MENLO PARK, Calif., May 12, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with athenahealth, a leading provider of network-enabled software and services for healthcare practices and systems nationwide. This collaboration will integrate ordering of GRAIL's Galleri® multi-cancer early detection (MCED) test into athenaCoordinator Core, a service designed to help streamline laboratory order transmission and care coordination for healthcare facilities. The integration will be provided through athenaOne, athenahealth's leading cloud-based electronic health record (EHR) solution.

      5/12/25 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Ofman Joshua J. sold $1,635,867 worth of shares (48,213 units at $33.93), decreasing direct ownership by 9% to 511,460 units (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      5/5/25 9:44:24 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Chief Financial Officer Freidin Aaron sold $1,396,220 worth of shares (41,150 units at $33.93), decreasing direct ownership by 12% to 294,020 units (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      5/5/25 8:46:25 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Chief Executive Officer Ragusa Robert P sold $3,190,608 worth of shares (94,035 units at $33.93), decreasing direct ownership by 11% to 734,627 units (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      5/5/25 8:44:41 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Financials

    Live finance-specific insights

    See more
    • GRAIL Reports First Quarter 2025 Financial Results

      Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Cash Position of $677.9 Million Provides Runway Into 2028 MENLO PARK, Calif., May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025. Total revenue in the first quarter was $31.8 million, representing 19% growth year over year, and Galleri revenue was $29.1 m

      5/13/25 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL to Announce First Quarter 2025 Financial Results

      MENLO PARK, Calif., April 29, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2025 following the close of market on Tuesday, May 13, 2025. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. First Quarter 2025 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the inves

      4/29/25 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results

      Sold More than 137,000 Galleri® Tests in 2024, Growing U.S. Galleri Revenue 45% Year-Over-Year to $108.6 Million Completed Study Visits for Two Registrational Studies in July to Support Modular PMA Submission for Galleri On Track for Continued Commercial Growth in 2025 with TRICARE Coverage and Recent Announcement of Quest Integration Moderated Cash Burn, Ending 2024 with a Cash Position of $767M, Extending Runway into 2028 MENLO PARK, Calif., Feb. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2024 and provided business

      2/20/25 4:02:00 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on GRAIL with a new price target

      Canaccord Genuity initiated coverage of GRAIL with a rating of Buy and set a new price target of $32.00

      4/21/25 8:38:45 AM ET
      $GRAL
      Medical Specialities
      Health Care
    • Morgan Stanley initiated coverage on GRAIL with a new price target

      Morgan Stanley initiated coverage of GRAIL with a rating of Equal-Weight and set a new price target of $16.00

      11/27/24 7:29:05 AM ET
      $GRAL
      Medical Specialities
      Health Care
    • Wolfe Research initiated coverage on GRAIL

      Wolfe Research initiated coverage of GRAIL with a rating of Peer Perform

      11/15/24 7:46:11 AM ET
      $GRAL
      Medical Specialities
      Health Care